tiprankstipranks
pc:nrgth

NRG Therapeutics

NRG Therapeutics is a neuroscience drug discovery company focused on developing disease-modifying mitochondrial therapeutics aimed at slowing or halting the progression of neurodegenerative disorders such as Parkinson's disease and amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND). The company is pioneering a novel approach by targeting the mitochondrial permeability transition pore (mPTP) to protect neurons, reduce neuroinflammation, and improve motor function. Its lead candidate, NRG5051, has completed IND-enabling studies and is set to enter clinical trials in early 2026. Based in the UK, NRG Therapeutics is supported by a consortium of international life science investors and has received multiple awards to advance its innovative research and development programs.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$67M
Total Amount Raised$67M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$67M
Latest Funding Amount$67M
Latest Funding RoundSeries B
Latest Funding RoundSeries B
Post-Money Valuation
Post-Money Valuation

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Sep 08, 2025
Series B
$67.00M

Related News and Analysis